Quintrio
Home

PHARMACEUTICAL PREPARATIONS

IGC Pharma, Inc.

IGC

IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.

Last trade $0.1874
Day change +$0.0124 (+7.09%)
Day range $0.176 – $0.197
Volume 282,927
Market cap $20M

Open XASE

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$21M
Price / earnings
—
Price / book
3.23×
Price / sales
19.08×
EV / sales
19.52×
EV / EBITDA
-2.2×

Profitability

Earnings per share
-$0.08
Return on assets
-94.61%
Return on equity
-141.59%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.13×
Current ratio
0.42×
Quick ratio
0.21×
Cash ratio
0.12×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$6.12M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for IGC, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q4 FY2025 Mar 31, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Mar 31, 2024
Revenue$328K$265K$317K$191K$328K$330K$330K$295K
Cost of revenue$267K$217K$262K$92K$174K$176K$176K$124K
Gross profit$61K$48K$55K$99K$154K$154K$154K$171K
Selling, general and administrative$979K$1.44M$1.24M$1.41M$1.21M$569K$570K$1.49M
Research and development$1.01M$1.39M$1.27M$1.59M$851K$997K$997K$855K
Total operating expenses$1.99M$2.83M$2.51M$3M$2.06M$1.57M$1.57M-$282K
Operating income-$1.93M-$2.78M-$2.46M-$2.9M-$1.91M-$1.41M-$1.41M$453K
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$2.05M-$2.94M-$2.4M-$1.82M-$1.6M-$1.2M-$1.2M-$2.89M
Income taxes$0$0$0$0$0$0$0$0
Net income-$2.05M-$2.94M-$2.4M-$1.82M-$1.6M-$1.2M-$1.2M-$2.89M
Net income attributable to common shareholders-$2.05M-$2.94M-$2.4M-$1.82M-$1.6M-$1.2M-$1.2M-$2.89M
EBITDA-$1.87M-$2.73M-$2.4M-$2.78M-$1.76M-$1.28M-$1.26M-$2.05M
Basic earnings per share-$0.02-$0.03-$0.02-$0.02-$0.02-$0.02-$0.02-$0.04
Diluted earnings per share-$0.02-$0.03-$0.02-$0.02-$0.02-$0.02-$0.02-$0.04

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Guardian Pharmacy Services (GRDN) Q3 Earnings and Revenues Surpass Estimates

Guardian Pharmacy Services reported Q3 2026 earnings of $0.33 per share, beating consensus estimates of $0.32, with revenues of $371.07 million exceeding expectations by 1.96%. The company has surpassed consensus EPS estimates in all four of the last quarters. However, the stock received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.

GlobeNewswire Inc.

Alzheimer's Disease Clinical Trial and Competitive Landscape Enters a New Phase as 200+ Companies Advance Clinical Programs | DelveInsight

Over 200 companies are advancing more than 240 pipeline Alzheimer's disease therapies across various clinical development stages. The market is being driven by an aging population, rising disease prevalence, and the emergence of disease-modifying therapies that enable earlier intervention and biomarker-guided care. Two therapies have recently received FDA approval: KISUNLA (donanemab) from Eli Lilly and LEQEMBI (lecanemab-irmb) from Eisai/Biogen, both targeting amyloid plaques to slow disease progression.

GlobeNewswire Inc.

Cannabinoid Agonist Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

The cannabinoid agonist market is gaining momentum with expanding medical cannabis legalization and growing clinical validation for treating chronic pain, epilepsy, and inflammatory conditions. Over 20 pharmaceutical companies are actively developing cannabinoid agonist drugs with promising pipeline candidates.

Benzinga

Why VBI Vaccines Are Trading Lower By Over 23%; Here Are 20 Stocks Moving Premarket

Gainers Akumin Inc. (NASDAQ: AKU) shares surged 58.2% to $0.2865 in pre-market trading. Akumin recently named Krishna Kumar as President and Chief Operating Officer of the Company. Mullen Automotive, Inc. (NASDAQ: MULN) shares gained 52.8% to $0.2612 in pre-market trading. Mullen Automotive shares jumped 69% on Wednesday after the company announced the retention of a law group to investigate possible naked short selling. Micromobility.com Inc. (NASDAQ: MCOM) shares rose 19.8% to $0.1354 in pre-market trading. micromobility.com recently announced a strategic realignment to strengthen its financial position and drive profitability. Caravelle International Group (NASDAQ: CACO) rose 19.6% to $0.6399 in pre-market trading. AIM ImmunoTech Inc. (NYSE: AIM) gained 18.3% to $0.7690 in pre-market trading after declining 3% on Wednesday. Histogen Inc. (NASDAQ: HSTO) rose 18% to $0.8563 in pre-market trading. Histogen announced its decision to pause further development of its programs and commence a process to explore strategic alternatives. IGC Pharma, Inc. (NYSE: IGC) shares rose 14.7% to $0.39 in pre-market trading after gaining around 5% on Wednesday. IronNet, Inc. (NYSE: IRNT) shares climbed 13.9% to $0.2392 in pre-market trading after gaining ...

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Apr 19, 20131-for-10reverse split